SURGE Therapeutics

Recent Finacing

Series B

Recent Raise

$32M

SURGE Therapeutics develops an injectable biodegradable hydrogel platform (SURGERx) for intraoperative, localized extended-release cancer immunotherapies; lead candidate STM-416 is in a Phase 1/2a bladder cancer trial.

Founded 2016

Massachusetts, United States

1-10

Private

surgetx.com

Highlights

Focus Areas

Biotechnology

Health Care

Life Science

Recent Investors

Financials

$58M

Total Raised

2

Funding rounds

10

Investors

Team

Upgrade to view the team

See the team members at SURGE Therapeutics.